First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
The Pharma Data
OCTOBER 22, 2020
AstraZeneca will book all sales revenue and will pay Innate low double-digit to mid-teen percentage royalties on net sales worldwide except in Europe where Innate Pharma will receive 50% share of the profits and losses in the territory. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.
Let's personalize your content